NVAX
Novavax Inc.
Company Overview
| Mkt Cap | $1.21B | Price | $8.54 |
| Volume | 1.96M | Change | +1.37% |
| P/E Ratio | -6.5 | Open | $8.41 |
| Revenue | $682.2M | Prev Close | $8.42 |
| Net Income | $-187.5M | 52W Range | $5.01 - $11.97 |
| Div Yield | N/A | Target | $13.78 |
| Overall | 47 | Value | 60 |
| Quality | 47 | Technical | 36 |
No chart data available
About Novavax Inc.
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Latest News
Novavax (NVAX) Receives a Sell from Bank of America Securities
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NVAX | $8.54 | +1.4% | 1.96M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |